Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 10/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679480 | 1.00 | AKR1C3 (0.44) | AKR1C3APEX1RXRARXRBNR4A2 | |
| SCHEMBL8956732 | 0.93 | AKR1C3 (0.39) | AKR1C3APEX1 | |
| SCHEMBL2468016 | 0.77 | AKR1C3 (0.41) | AKR1C3APEX1 | |
| SCHEMBL9176584 | 0.76 | CYP1A2 (0.31) | — | |
| SCHEMBL2597835 | 0.76 | — | — | |
| SCHEMBL156601 | 0.76 | — | — | |
| SCHEMBL8930023 | 0.73 | ALDH1A1 (0.41) | — | |
| SCHEMBL7865928 | 0.73 | — | — | |
| SCHEMBL27824143 | 0.72 | AKR1C3 (0.35) | AKR1C3 | |
| SCHEMBL18154639 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995778-B1 | Coating composition with improved intercoat adhesion | BASF CORP (US) | 2005-06-15 | — | — | EP | claimed |
| EP-0738740-B1 | Curable coating composition | BASF CORP (US) | 2003-07-23 | — | — | EP | claimed |
| EP-0738739-B1 | Multiple layer coating method | BASF CORP (US) | 2002-06-26 | — | — | EP | claimed |
| EP-0242080-B1 | COPOLYMER COMPOSITIONS | PARAGON OPTICAL INC (US) | 1992-12-16 | — | — | EP | claimed |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2016165979-A1 | DIHYDRO-OLIGO-CYCLOPENTADIENYL (METH)ACRYLATES | BASF SE (DE) | 2016-10-20 | — | — | WO | disclosed |
| EP-1144474-A1 | AQUEOUS REACTIVE PUTTY (I) | Bayer Aktiengesellschaft (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000037523-A1 | AQUEOUS REACTIVE PUTTY (I) | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | AKR1C3 3433/4885APEX1 29/4885RXRA 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.